iRhythm (IRTC): Capital Research Reports 1.51M Shares, 4.7% Stake
Capital Research Global Investors filed Amendment No.4 to a Schedule 13G/A reporting its holdings in iRhythm Technologies, Inc. (Common Stock, CUSIP 450056106).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Capital Research Global Investors filed Amendment No.4 to a Schedule 13G/A reporting its holdings in iRhythm Technologies, Inc. (Common Stock, CUSIP 450056106). The filing states CRGI holds 1,506,864 shares, representing 4.7% of the 31,925,267 shares believed outstanding, with sole voting and dispositive power for that amount. The filing cites an event date of 06/30/2025 and is signed on 08/05/2025.
The filing describes CRGI as a division of Capital Research and Management Company and related investment management entities that provide services under the name "Capital Research Global Investors." The statement includes a certification that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Insights
TL;DR: CRGI reports a 4.7% passive stake (1,506,864 shares) in IRTC; below 5% threshold, limited governance impact.
The filing discloses a non-controlling position of 1,506,864 shares, representing 4.7% of the 31,925,267 shares believed outstanding. Voting and dispositive power are reported as sole for that exact amount, and the certification states the holdings are in the ordinary course of business and not intended to influence control. From an investment-analysis perspective, this is a notable institutional position but falls below common 5% thresholds that often trigger heightened investor scrutiny or additional disclosure obligations.
TL;DR: The filing confirms sole voting/dispositive power for 1,506,864 shares and certifies holdings not intended to influence issuer control.
The Schedule 13G/A clarifies the reporting person is Capital Research Global Investors, a division of Capital Research and Management Company and affiliated investment management entities, organized in Delaware. The report emphasizes a passive ownership stance with explicit certification that the stake was not acquired to change or influence company control. Given the 4.7% level, this position is material as an institutional holding but does not, by itself, indicate governance intentions or control actions disclosed in this filing.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake did Capital Research Global Investors report in iRhythm (IRTC)?
What type of SEC filing did Capital Research Global Investors submit for IRTC?
What date is listed as the event requiring the Schedule 13G filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.